TD Asset Management Inc Grows Stock Holdings in IQVIA Holdings Inc. $IQV

TD Asset Management Inc grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 11.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 117,277 shares of the medical research company’s stock after acquiring an additional 11,997 shares during the period. TD Asset Management Inc owned about 0.07% of IQVIA worth $22,276,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. lifted its stake in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares in the last quarter. Westside Investment Management Inc. lifted its position in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares in the last quarter. Atlantic Union Bankshares Corp purchased a new position in IQVIA in the 3rd quarter worth approximately $36,000. Asset Dedication LLC grew its position in IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 168 shares in the last quarter. Finally, Rothschild Investment LLC raised its stake in shares of IQVIA by 85.5% during the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 124 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IQV has been the topic of several analyst reports. Stifel Nicolaus dropped their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Truist Financial lowered their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. TD Cowen upped their price objective on IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Finally, BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $231.80.

IQVIA Price Performance

Shares of NYSE:IQV opened at $179.09 on Friday. The stock has a market cap of $30.39 billion, a price-to-earnings ratio of 22.79, a PEG ratio of 1.72 and a beta of 1.37. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The stock’s 50 day moving average price is $212.19 and its 200 day moving average price is $208.00.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.